Rafizadeh Reza, Turgeon Ricky D, Batterink Josh, Su Victoria, Lau Anthony
, BScPharm, ACPR, is a Clinical Pharmacist, Mental Health and Substance Use, Burnaby Hospital, Burnaby, British Columbia.
, BScPharm, ACPR, PharmD, is a Pharmacotherapeutic Specialist, Neurosurgery, Vancouver General Hospital, Vancouver, British Columbia.
Can J Hosp Pharm. 2016 Nov-Dec;69(6):454-459. doi: 10.4212/cjhp.v69i6.1608. Epub 2016 Dec 23.
Symptomatic venous thromboembolism (VTE) occurs in about 1% of patients within 3 months after admission to a medical unit. Recent evidence for thromboprophylaxis in an unselected medical inpatient population has suggested only a modest net benefit. Consequently, guidelines recommend careful risk stratification to guide thromboprophylaxis.
To compare candidacy for thromboprophylaxis according to 4 risk stratification models: a regional preprinted order (PPO) set used in the study institution, the Padua Prediction Score, and the IMPROVE predictive and associative risk assessment models.
A retrospective review of health records was undertaken for patients with no contraindication to pharmacologic thromboprophylaxis who were admitted to the internal medicine service of a teaching hospital between April and July 2013.
Of the 298 patients in the study cohort, 238 (80.0%) received pharmacologic thromboprophylaxis on admission, ordered according to the regional PPO. However, according to the Padua and the IMPROVE predictive risk assessment models, only 64 (21.5%) and 21 (7.0%) of the patients, respectively, were eligible for thromboprophylaxis at the time of admission. On the basis of risk factors identified during the subsequent hospital stay, 54 (18.1%) of the patients were eligible for thromboprophylaxis according to the IMPROVE associative model. Chance-corrected agreement between the PPO and the published risk assessment models was generally poor, with kappa coefficients of 0.109 for the PPO compared with the Padua Prediction Score and 0.013 for the PPO compared with the IMPROVE predictive model.
These data suggest that quantitative models such as the Padua Prediction Score and the IMPROVE models identify more patients at low risk of venous thromboembolism than do in-hospital qualitative risk assessment models. Adoption of these guideline-based risk assessment models for predicting thromboembolic risk in medical inpatients could reduce the use of pharmacologic thromboprophylaxis from 80% to as low as 7%. Further external prognostic validation of risk assessment models and impact analysis studies may show improvements in safety and resource utilization.
症状性静脉血栓栓塞症(VTE)在入住内科病房的患者中,约1%会在入院后3个月内发生。近期针对未筛选的内科住院患者进行血栓预防的证据表明净获益不大。因此,指南建议进行仔细的风险分层以指导血栓预防。
根据4种风险分层模型比较血栓预防的适用情况:研究机构使用的区域预印医嘱(PPO)集、帕多瓦预测评分以及IMPROVE预测和关联风险评估模型。
对2013年4月至7月间入住一家教学医院内科且无药物性血栓预防禁忌症的患者的健康记录进行回顾性分析。
研究队列中的298例患者中,238例(80.0%)入院时接受了根据区域PPO开具的药物性血栓预防治疗。然而,根据帕多瓦和IMPROVE预测风险评估模型,入院时分别只有64例(21.5%)和21例(7.0%)患者符合血栓预防条件。根据后续住院期间确定的风险因素,根据IMPROVE关联模型,54例(18.1%)患者符合血栓预防条件。PPO与已发表的风险评估模型之间的机遇校正一致性普遍较差,PPO与帕多瓦预测评分的kappa系数为0.109,PPO与IMPROVE预测模型的kappa系数为0.013。
这些数据表明,诸如帕多瓦预测评分和IMPROVE模型等定量模型比医院内定性风险评估模型能识别出更多静脉血栓栓塞低风险患者。采用这些基于指南的风险评估模型来预测内科住院患者的血栓栓塞风险,可将药物性血栓预防的使用率从80%降至低至7%。风险评估模型的进一步外部预后验证和影响分析研究可能会显示在安全性和资源利用方面有所改善。